David Haffie, DO
Family Medicine · Escondido, CANPI 1649252636
Payments from drug & device makers
Across 481 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$2K
- Novo Nordisk$954
- GSK$899
- Lilly USA, LLC$639
- Boehringer Ingelheim$475
- plus $3K from 35 others
What the payments were for
- Food & beverage$8,90999%
- Education$781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 92 | $1,954 |
| AbbVie(2 entities) | 62 | $1,502 |
| Novo Nordisk | 67 | $954 |
| GSK | 56 | $899 |
| Lilly USA, LLC | 38 | $639 |
| Boehringer Ingelheim | 24 | $475 |
| Pfizer | 16 | $296 |
| Amarin Pharma, Inc. | 12 | $218 |
| Merck | 12 | $206 |
| Amgen | 8 | $150 |
| Johnson & Johnson | 9 | $147 |
| Bayer | 7 | $145 |
| Abbott | 8 | $141 |
| Dexcom, Inc. | 5 | $134 |
| Esperion Therapeutics, Inc. | 8 | $131 |
| Sanofi-aventis U.S. LLC | 7 | $111 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $104 |
| Kowa Pharmaceuticals America, Inc. | 5 | $83 |
| Boston Scientific | 2 | $69 |
| IBSA Pharma Inc. | 5 | $63 |
| Biohaven Pharmaceuticals, Inc. | 4 | $63 |
| Gilead | 2 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Si-bone, Inc. | 2 | $42 |
| Astellas Pharma US Inc | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Novartis | 2 | $33 |
| Eisai Inc. | 1 | $27 |
| Teleflex LLC | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Stryker | 1 | $19 |
| Lucid Diagnostics Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Halozyme Inc | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Duchesnay USA Incorporated | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Stimwave Technologies Incorporated | 1 | $13 |
| Sumitomo Pharma America, Inc. | 1 | $3 |
How this compares
$8,987 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $99,658 |
| EliquisApixaban | 81 | $78,773 |
| FarxigaDapagliflozin Propanediol | 35 | $56,582 |
| TrulicityDulaglutide | 28 | $47,864 |
| JardianceEmpagliflozin | 25 | $42,493 |
| MounjaroTirzepatide | 21 | $29,431 |
| JanuviaSitagliptin Phosphate | 17 | $29,319 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $24,766 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $13,723 |
| MyrbetriqMirabegron | 17 | $12,466 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $10,934 |
| Atorvastatin Calcium | 617 | $6,222 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $5,393 |
| Omeprazole | 257 | $5,138 |
| Rosuvastatin Calcium | 303 | $4,037 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $954 | $99,65863 claims |
| PfizerEliquis | $296 | $78,77381 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $639 | $77,29549 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,954 | $75,69866 claims |
| Boehringer IngelheimJardiance | $475 | $42,49325 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $899 | $35,70144 claims |
| MerckJanuvia | $206 | $29,31917 claims |
| Astellas Pharma US IncMyrbetriq | $39 | $12,46617 claims |
| AbbVieSynthroid | $1,502 | $2,24437 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Escondido
- James SchultzEscondido$2.5M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.